A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification

Current Medical Research and Opinion

Volumn 27, Issue 12, 2011, Pages 2235-2239

  Bucci Jr , Frank A ^a   David Waterbury, L ^b  

^a Bucci Laser Vision Institute   (United States)

^b Raven Biosolutions LLC   (United States)

Author keywords

Amfenac; Aqueous penetration; Bromfenac; Ketorolac; Nepafenac

Indexed keywords

BROMFENAC; KETOROLAC; NEPAFENAC;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CATARACT; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA; DRUG PENETRATION; FEMALE; HUMAN; IONIZATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PARACENTESIS; PHACOEMULSIFICATION; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZENEACETAMIDES; BENZOPHENONES; BROMOBENZENES; CATARACT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KETOROLAC; MALE; MIDDLE AGED; PHENYLACETATES;

EID: 81855221195     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.626018     Document Type: Article

References (25)

1. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010;55:108-33
2. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42:1-11
3. Samiy N, Foster CS. The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Int Ophthalmol Clin 1996;36:195-206
4. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003;217:89-98
5. Koay P. The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology. Br J Ophthalmol 1996;80:480-5
6. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790-804
7. Xibrom. Irvine: ISTA Pharmaceuticals, 2010
8. Donnenfeld ED, Holland EJ, Stewart RH, et al. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 2007;114:1653-62
9. Nevanac. Fort Worth: Alcon Laboratories, 2008
10. Acular LS. Irvine: Allergan, Inc., 2008
11. Acuvail. Irvine: Allergan, Inc., 2009
12. Donnenfeld ED, Perry HD, Wittpenn JR, et al. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokineticresponse curve. J Cataract Refract Surg 2006;32:1474-82
13. Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother 2006;7:99-107
14. Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin 2004;20:2015-19
15. Solomon KD, Donnenfeld ED, Raizman M, et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg 2004;30:1653-60
16. Bucci Jr FA, Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. Am J Ophthalmol 2007;144:146-7
17. Bucci Jr FA, Waterbury LD. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. J Cataract Refract Surg 2008;34:1509-12
18. Amico LM, Bucci FA Jr, Waterbury LD. Aqueous penetration of ketorolac 0.4% compared with bromfenac 0.09% in cataract patients: peak and trough drug concentations. Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL, USA, 2007
19. Bucci Jr FA, Waterbury LD. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. Adv Ther 2009;26:645-50
20. Donnenfeld ED, Nichamin LD, Hardten DR, et al. Twice-daily, preservativefree ketorolac 0.45% for treatment of inflammation and pain after cataract surgery. Am J Ophthalmol 2011;151:420-26
21. Garrett Q, Simmons PA, Xu S, et al. Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthalmol Vis Sci 2007;48:1559-67
22. Bucci FA Jr, Waterbury LD, Evans R, et al. Aqueous PGE2 inhibition of ketorolac tromethamine 0.45%, bromfenac 0.09% and nepafenac 0.1% in patients undergoing phacoemulsification. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL, USA, 2010
23. Chandler SP, Henderson BA, Gayton J, et al. Integrated phase 3 clinical trials of bromfenac sodium ophthalmic solution dosed once daily for ocular surgery. American Academy of Ophthalmology. Chicago, 2010
24. Baranano DE, Kim SJ, Edelhauser HF, et al. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol 2009;93:1387-90
25. Bucci Jr FA. Ketorolac versus bromfenac: review of 7 prospective randomized studies comparing PGE2 inhibition and aqueous penetration. ASCRS/ASOA 2011. San Diego: American Society Cataract Refractive Surgery, 2011